Abrdn
Signal active
Investment Firm
Overview
Abrdn enables its clients to plan, save, and invest for their futures. Abrdn is operating across three vectors that reflect how their clients interact with them. Abrdn has the full ecosystem of capabilities to enable our clients to be better investors.
Highlights
Founded
1825
Industry
Enterprise Software
Employees
10001+
Investment
15
Lead Investment
3
Exits
4
Stages
Early Stage Venture, Private Equity
Investor Type
N/A
Location
Europe
Contact Information
Social
Profile Resume
Abrdn, established in 1825 and headquartered in Europe., specializes in Early Stage Venture, Private Equity investments across Internet, Travel, Leisure, Financial Services, Finance, Lending, Asset Management, Impact Investing, Venture Capital, Biotechnology. The organization boasts a portfolio of 14 investments, with an average round size of $308.9M and 4 successful exits. Their recent investments include Viajo.com, Morgan Stanley, Chase Capital Partners, GP Investments, GE Equity. The highest investment round they participated in was $126.8B. Among their most notable exits are Viajo.com and Morgan Stanley. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Abrdn has made 15 investments. Their most recent investment was on Mar 27, 2024, when Sammaan Capital raised $347.9M.
Abrdn has made 1 diversity investments. Their most recent diversity investment was on Apr 30, 2024, when Qlaris Bio raised $24.0M.
investments
15
Diversity investments
1
Lead investments
3
Number of exits
4
Investments
15
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Mar 19, 2024 | Engrail Therapeutics | Life Science | 157.0M |
| Mar 27, 2024 | Sammaan Capital | Financial Services | 347.9M |
| Apr 30, 2024 | Qlaris Bio | Biotechnology | 24.0M |
| Jul 23, 2024 | - | - | 165.0M |
Exits
4
Funding Timeline
Funding rounds
15
Investors
0
Funds
1
Funding Rounds
15
Abrdn has raised 15 rounds. Their latest funding was raised on Jul 23, 2024 from a Series A - Third Arc Bio round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Mar 19, 2024 | Series B - Engrail Therapeutics | - | 157.0M | - |
| Mar 27, 2024 | Post-IPO Debt - Sammaan Capital | - | 347.9M | - |
| Apr 30, 2024 | Series B - Qlaris Bio | - | 24.0M | - |
| Jul 23, 2024 | Series A - Third Arc Bio | - | 165.0M | - |
Investors
2
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
| - | No | Funding Round - Abrdn | 464.0K |
| - | No | Venture Round - Abrdn | 4.6M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.